Hui Tang
Huashan Hospital · Innervo Technology LLC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hui Tang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:44 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06365879 · To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous UrticariaTaizhou Mabtech Pharmaceutical Co.,Ltd · completed · Chronic Spontaneous Urticaria · principal investigator
- N/ANCT02735096 · Testing an Intraoral Electronic Balance Aid for Vestibular ImbalanceInnervo Technology LLC · terminated · Vestibular Disorder · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:44 UTC. The ranking covers the 200 most relevant of 382 PubMed records, and a shared surname and initials can bring in a namesake. All 382 on PubMed
- 3,555 citationsRCR 120.7
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.J Hepatol · 2020352 citationsRCR 13.5
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.Lancet Oncol · 2010326 citationsRCR 8.5
- 298 citationsRCR 52.7
- The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.J Am Soc Nephrol · 2014234 citationsRCR 7.9
- 188 citationsRCR 17.5
- A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.Alzheimers Res Ther · 2021172 citationsRCR 11.3
- 167 citationsRCR 9.7
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).J Clin Oncol · 2023154 citationsRCR 10.8
- Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.J Immunother Cancer · 2023137 citationsRCR 12.3